Characterization of the anti-drug antibody (ADA) response caused by biotherapeutics, such as multi-domain biologics, antibody drug conjugates, and some monoclonal antibody drugs, can provide valuable information about the safety and efficacy of the drug. It can also pose a significant challenge to assay developers. As experience is gained with the increasing number of biologics and biosimilars on the market and in development, a more complete characterization of the clinical impact of ADA to these therapies will be critical to successful launch and post-launch strategies.
The Scientist brings together a panel of experts to discuss strategies to study and characterize immune responses and highlight emerging bioanalytical techniques used for their assessment. The panelists will discuss immunoassay methods for measuring immunogenicity, as well as the use of automation to characterize biologics-induced ADA, including both the use of assays to mitigate soluble target interference and to detect IgG4 ADAs. Attendees will have an ...
